滚动资讯
BioWorldSecond CRL for Replimune’s RP-1 for melanomaFierceBiotechFDA rejects Replimune’s melanoma prospect for second timeEndpoints NewsPlan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s pushEndpoints NewsBayer pharma executive predicts US-Europe price spreads will narrowBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-April 9, 2026Endpoints NewsFDA rejects Replimune cancer therapy, saying company didn't resolve trial doubtsBioPharma DiveFDA again spurns Replimune melanoma drugIlluminaWill Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Yahoo FinanceBioWorldIn the clinic for April 10, 2026BioWorldOther news to note for April 10, 2026BioWorldRegulatory actions for April 10, 2026
BioWorld 2026年4月10日

Second CRL for Replimune’s RP-1 for melanoma

Second CRL for Replimune’s RP-1 for melanoma

原文
暂时没有全文，请查看原始来源。

目录

59 全部